Type 2 diabetes trials in Poland
34 of 39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Where
- Belchatow, Bialystok, Bydgoszcz, Chojnice, Cracow, Częstochowa, Elblag, Gdynia, Katowice, Lodz, Olsztyn, Opole, Staszow, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 11,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00 - Phase 2Taking peopleA Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
- Where
- Białystok, Bydgoszcz, Gdansk, Katowice, Lublin, Tarnów, Warsaw, Wroclaw, Zamość
- Age
- 18 years and over
- People
- 330 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07112872 · EU 2024-520322-11-00 - Phase 3Not yet taking people in PolandA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
- Where
- Katowice, Malbork, Oswiecim, Plock, Staszow, Świnoujście, Warsaw
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931495 · EU 2026-525470-18-00 - Phase 3Not yet taking people in PolandA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Where
- Chorzów, Gdansk, Lublin, Olsztyn, Oswiecim, Swiecie, Warsaw, Zabrze
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931547 · EU 2026-525471-13-00 - Phase 3Not yet taking people in PolandAMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
- Where
- Bialystok, Chojnice, Lublin, Piotrkow Trybunalski, Tarnów, Warsaw, Wrocław, Zabrze
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931573 · EU 2026-525472-26-00 - Phase 3Not yet taking people in PolandA Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
- Where
- Cracow, Leczna, Malbork, Skierniewice, Sosnowiec
- Age
- 18 years and over
- People
- 1,060 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931599 · EU 2026-525474-20-00 - No phaseTaking peopleType 2 Diabetes and Pregnancy a Single-arm Interventional Study
- Where
- Poznan
- Age
- 18 years to 45 years
- People
- 20
- Run by
- Poznan University of Medical Sciences
See details and how to joinNCT07602036 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Where
- Bialystok, Bydgoszcz, Cracow, Gdynia, Lublin, Opole, Tarnów, Tychy, Warsaw, Zamość
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Białystok, Bydgoszcz, Debica, Lublin, Pabianice, Poznan, Ruda Śląska, Siedlce, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Where
- Gdansk, Lublin, Poznan, Wrocław, ZDROWIE OSTEO-MEDIC S.C. L. i A. Racewicz, A. i J. Supronik
- Age
- 18 years and over
- People
- 954 worldwide
- Run by
- Pfizer
See details and how to joinNCT07595549 · EU 2026-525318-75-00 - Phase 3Taking peopleA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
- Where
- Bialystok, Cracow, Mazowieckie, Warsaw
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07843485 · EU 2026-526189-25-00 - No phaseTaking peopleContinuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin
- Where
- Bialystok
- Age
- 18 years to 65 years
- People
- 50
- Run by
- Medical University of Bialystok
See details and how to joinNCT07919236 - Phase 2Taking peopleA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Where
- Bialystok, Cracow, Gdansk, Lodz, Lublin, Tarnów, Warsaw, Warszawa, Wroclaw
- Age
- 18 years to 75 years
- People
- 200 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06897475 · EU 2024-520328-27-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Where
- Bialystok, Bydgoszcz, Cracow, Elblag, Lodz, Lublin, Ruda Śląska, Zabrze
- Age
- 18 years and over
- People
- 1,035 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00 - Phase 3Not yet taking people in PolandA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- Where
- Bialystok, Białystok, Krakow, Kraków, Lublin, Piotrkow Trybunalski
- Age
- 45 years to 64 years
- People
- 3,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00 - Phase 3Taking peopleA Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Where
- Bialystok, Częstochowa, Kielce, Lodz, Lublin, Poznan, Radom, Warsaw
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Where
- Bialystok, Cracow, Elblag, Gdynia, Katowice, Legnica, Lodz, Poznan, Radzionkow, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 2,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Where
- Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan, Radzionków, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 1,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784270 - No phaseTaking peopleClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
- Where
- Gdansk, Krakow, Kraśnik, Lublin, Nadarzyn, Warsaw
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06704672 - Phase 3Taking peopleA Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Where
- Bialystok, Cracow, Lodz, Lublin, Poznan, Radom, Warsaw
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662213 · EU 2025-523933-24-00 - Phase 3Taking peopleEfficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
- Where
- Biała Podlaska, Bydgoszcz, Cracow, Czestochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz, Łódź, Lublin, Poznan, Pulawy, Siedlce, Staszow, Torun, Warsaw, Warszawa, Wroclaw, Wrocław
- Age
- 18 years and over
- People
- 549 worldwide
- Run by
- Ascletis Pharma (China) Co. Ltd.
See details and how to join2026-526336-39-00 - Phase 3Taking peopleA Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
- Where
- Bialystok, Bydgoszcz, Kielce, Krakow, Lodz, Lublin, Poznan, Radom, Warsaw
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07667803 - Phase 3Taking peopleA Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight
- Where
- Bialystok, Cracow, Elblag, Gdynia, Katowice, Legnica, Lodz, Poznan, Radzionkow, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524616-11-00 - Phase 2Taking peopleA Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
- Where
- Bialystok, Białystok, Kielce, Lublin, Oswiecim
- Age
- 18 years to 75 years
- People
- 300 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07668388 · EU 2026-525465-42-00 - Phase 4Taking peoplePancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
- Where
- Zabrze
- Age
- 35 years to 75 years
- People
- 100
- Run by
- Silesian Centre for Heart Diseases
See details and how to joinNCT07852988